Bio Path Holdings Stock Beta
BPTHDelisted Stock | USD 0.19 0.01 5.00% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Bio Path's long-term financial health and intrinsic value.
Bio |
Bio Path Holdings OTC Stock Beta Analysis
Bio Path's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Bio Path Beta | 0.05 |
Most of Bio Path's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bio Path Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
CompetitionIn accordance with the recently published financial statements, Bio Path Holdings has a Beta of 0.05. This is 94.19% lower than that of the Biotechnology sector and 96.4% lower than that of the Health Care industry. The beta for all United States stocks is 133.33% lower than that of the firm.
Bio Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bio Path's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Bio Path could also be used in its relative valuation, which is a method of valuing Bio Path by comparing valuation metrics of similar companies.Bio Path is currently under evaluation in beta category among its peers.
As returns on the market increase, Bio Path's returns are expected to increase less than the market. However, during the bear market, the loss of holding Bio Path is expected to be smaller as well.
Bio Fundamentals
Return On Equity | -11.6 | ||||
Return On Asset | -1.94 | ||||
Current Valuation | 531.06 K | ||||
Shares Outstanding | 5.77 M | ||||
Shares Owned By Institutions | 7.41 % | ||||
Number Of Shares Shorted | 79.35 K | ||||
Price To Earning | (6.21) X | ||||
Price To Book | 2.33 X | ||||
EBITDA | (15.76 M) | ||||
Net Income | (16.08 M) | ||||
Cash And Equivalents | 17.02 M | ||||
Cash Per Share | 2.38 X | ||||
Total Debt | 113 K | ||||
Debt To Equity | 0.01 % | ||||
Current Ratio | 15.57 X | ||||
Book Value Per Share | (0.19) X | ||||
Cash Flow From Operations | (11.54 M) | ||||
Short Ratio | 0.43 X | ||||
Earnings Per Share | (8.34) X | ||||
Target Price | 12.0 | ||||
Number Of Employees | 10 | ||||
Beta | 0.05 | ||||
Market Capitalization | 1.21 M | ||||
Total Asset | 3.22 M | ||||
Retained Earnings | (107.61 M) | ||||
Working Capital | 1.14 M | ||||
Current Asset | 9.59 M | ||||
Current Liabilities | 937 K | ||||
Net Asset | 3.22 M |
About Bio Path Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bio Path Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bio Path using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bio Path Holdings based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
USOI | Credit Suisse X Links | |
ULTY | Tidal Trust II | |
CONY | YieldMax N Option | |
BCAT | BlackRock Capital Allocation | |
PDI | Pimco Dynamic Income |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Other Consideration for investing in Bio OTC Stock
If you are still planning to invest in Bio Path Holdings check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Bio Path's history and understand the potential risks before investing.
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
CEOs Directory Screen CEOs from public companies around the world | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |